Vaccine Candidate Articles & Analysis
22 articles found
It allows for the identification of suitable donors and improved matching processes, thereby enhancing graft survival rates. Implications for Vaccine Development In vaccine development, concerns about cross-reactivity can influence the safety and effectiveness of the vaccine. Researchers aim to create vaccines that elicit strong ...
However, despite the fact that aluminum adjuvants in vaccines have been used in enhancing vaccine immune responses for nearly decades, the molecular mechanisms of aluminum adjuvants are still not fully understood. ...
As of January 1, 2023, global vaccine development includes a total of 966 vaccine candidates, of which 23% (220) are traditional inactivated or attenuated vaccines. ...
Interestingly, an investigational tuberculosis vaccine candidate was found to be significantly effective against the disease in the trial phase conducted in Kenya and Zambia, making it a potential vaccine in the future. ...
Abera’s vaccine delivery platform works as a plug-and-play system where known or novel antigens can be engineered onto our delivery platform to create effective, multivalent vaccines that are cost-effective and fast to produce. We actively work together with academia and industry to enable the use of our vaccine delivery platform in design ...
“The M2SR vaccine candidate has already shown a robust safety profile in adults, and we look forward to advancing scientific understanding of the potential benefits of M2SR in ...
Results will inform protocol design of Phase 1/2 clinical trial of Company's lead HSV-2 therapeutic vaccine candidate WOBURN, Mass. and OXFORD, England, Aug. 15, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced the launch of a clinical ...
Rational Vaccines' experimental vaccine candidate for herpes simplex virus type 2 (HSV-2), the primary cause of genital herpes, is showing promise in preclinical studies. Massachusetts-based Rational Vaccines said findings from a pilot study funded by the National Institutes of Health showed that RVX201, its lead ...
NLS) have provided the following observations: Mice vaccinated with HSV-2 0?NLS showed an improved antibody response compared to vaccination with a subunit vaccine candidate, Mice immunized with HSV-2 ...
People infected with either of these diseases have a 50% to 100% chance of dying. There is already a vaccine approved for use on horses and a modified vaccine has entered human clinical trials. ...
After being exposed to malaria, control monkeys that had not been vaccinated developed parasite levels three and a half times that of the vaccinated monkeys. ...
“Current vaccines are strain-specific and in recent years they have had low efficacy against H3N2 influenza, especially when the vaccine is mismatched to circulating virus,” said Dr. ...
LONDON, June 28, 2021 (GLOBE NEWSWIRE) – Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision off-the-shelf and personalized peptide cancer immunotherapies, today announced the publication of a peer-reviewed article titled “A Peptide Vaccine Candidate ...
This study will evaluate a monovalent H3N2 flu vaccine candidate, as compared to a licensed quadrivalent vaccine that is considered the current standard of care for adults aged 65 and above. ...
The study demonstrated that, following a vaccination using Micron’s technology, the immune response was as strong, or stronger, than vaccination by intramuscular injection. In addition, while the safety profile for Micron’s technology and intramuscular vaccination were similar, a survey showed a strong preference for Micron’s ...
A gold rush is on to find a vaccine for COVID-19. According to the World Health Association (WHO) in early May, there are more than 100 projects around the world centered on the development of a vaccine for the coronavirus. Eight candidate vaccines are already being tested in people in clinical trials. Once an effective ...
UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccineTweet this CoroFlu will build on the backbone of FluGen’s flu vaccine candidate known as M2SR. Based on an invention by UWMadison virologists and FluGen co-founders Yoshihiro Kawaoka and Gabriele Neumann, M2SR is a self-limiting version of the influenza virus that ...
With researchers ramping up efforts to develop a COVID-19 vaccine, progress has been achieved at unprecedented speed. In just two months, the first vaccine candidate entered clinical trials. ...
“With the spray drying technology, we have been able to achieve positive outcomes on our flagship vaccine candidate and are planning to extend the technology to other antigens and biopharmaceuticals as ...
ByBUCHI
Here, we tested a prophylactic live-attenuated vaccine against herpes simplex virus type 1 (HSV-1), a widespread human pathogen that can cause corneal blindness. ...